Please assess the completion status of the following clinical trial:

Trial Title: Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* attend the COVID-19 Fangcang Shelter Hospitals in Shanghai, China~* with laboratory-confirmed COVID-19~* compliance with the diagnostic criteria for mild COVID-19~* age 3 to 18 years.~Exclusion Criteria:~* with underlying disease(s) such as chronic pulmonary disease, immunodeficiency, tumors, etc.,~* allergy or intolerance to taking Chinese medicine herbs or compound pholcodine oral solution~* with poor compliance (defined as inability to comply with the protocol)~* decline to participate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: EXPERIMENTAL): receive oral HSBDG for 5 consecutive days
- control group (Type: OTHER): receive compound pholcodine oral solution for 5 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).